Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Published:2022-06 Issue:10343 Volume:399 Page:2294-2308
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Kamdar Manali,Solomon Scott R,Arnason Jon,Johnston Patrick B,Glass Bertram,Bachanova Veronika,Ibrahimi Sami,Mielke Stephan,Mutsaers Pim,Hernandez-Ilizaliturri Francisco,Izutsu Koji,Morschhauser Franck,Lunning Matthew,Maloney David G,Crotta Alessandro,Montheard Sandrine,Previtali Alessandro,Stepan Lara,Ogasawara Ken,Mack Timothy,Abramson Jeremy S

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

General Medicine

Reference15 articles.

1. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

2. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Tilly;Ann Oncol,2015

3. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12;Crump;J Clin Oncol,2014

4. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study;van Imhoff;J Clin Oncol,2017

Cited by 399 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposomes-enabled cancer chemoimmunotherapy;Biomaterials;2025-02

2. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies;Recent Patents on Anti-Cancer Drug Discovery;2024-12

3. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies;Blood;2024-09-12

4. A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma;British Journal of Haematology;2024-09-12

5. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11